Related Experiment Video

Updated: Aug 13, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

[Polyclonal B-cell activation by so-called immunopotentiation (immunostimulants)]

J Kekow1, G Hobusch, J Lüdemann

  • 1I. Medizinische Universitätsklinik Kiel.

Deutsche Medizinische Wochenschrift (1946)
|July 14, 1989
PubMed

Immuno-augmentation with substances of bacterial origin was studied in vitro for its ability to induce polyclonal B-cell activation. Biostim, Broncho-Vaxom, Omnadin, Paspat and OK 432 were compared for their B-cell mitogenicity with classical polyclonal B-cell activators (Staph. aureus Cowan I, KlebsM, Pokeweed mitogen). B-cell mitogenicity, as measured by 3H-thymidine incorporation into proliferating blood B-cells, was not induced by any of the studied preparations. On the other hand, OK 432 produced a T-cell dependent and Biostim a T-cell independent blood B-cell differentiation in immunoglobulin producing cells. However, the extent of immunoglobulin production was clearly less than with the polyclonal B-cell activator KlebsM. These results demonstrate that, in some of the preparations, in vivo polyclonal B-cell activation can be expected to occur.

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...